Phathom Pharmaceuticals to Announce Q2 2024 Financial Results and Business Update on August 8, 2024

Phathom Pharmaceuticals, Inc., a biopharmaceutical company listed on Nasdaq under the ticker PHAT, has announced plans to host a live webcast to discuss its second quarter 2024 financial results and provide updates on its business progress. The webcast is scheduled for Thursday, August 8, 2024, at 8:30 am ET. Interested individuals can access the live webcast and additional presentation details via the News & Events section of the Phathom website. A recording of the webcast will be available for 90 days after the event.

Phathom Pharmaceuticals is dedicated to developing and commercializing innovative treatments for gastrointestinal diseases. The company holds exclusive rights to vonoprazan, a pioneering potassium-competitive acid blocker (PCAB). Vonoprazan is marketed in the United States under the brand name VOQUEZNA® in tablet form for treating heartburn associated with Non-Erosive Gastroesophageal Reflux Disease (GERD) in adults. It is also used for the healing and maintenance of healing of Erosive GERD and its associated heartburn. Additionally, vonoprazan is available as part of VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for treating H. pylori infection in adults. These combination packs include vonoprazan tablets, amoxicillin capsules, and clarithromycin tablets (TRIPLE PAK®) or vonoprazan tablets and amoxicillin capsules (DUAL PAK®).

Phathom's commitment to addressing gastrointestinal conditions is evident through its innovative approach and strategic in-licensing of vonoprazan, which sets a new benchmark in acid suppression therapy. The company's focus on gastrointestinal treatments positions it as a significant player in the biopharmaceutical industry, particularly in the U.S. market where VOQUEZNA® products are available to patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!